References
- Price RW, Brew B, Sidtis J, Rosenblum M, Scheck A, Cleary P. The brain in AIDS: Central nervous system HIV infection and AIDS dementia complex. Science 1998; 239: 586–592
- Aggarwal SK, Gogu SR, Rangan SRS, Agrawal KC. Synthesis and biological evaluation of prodrugs of zidovudine. J Med Chem 1990; 33: 1505–1510
- Sriram D, Srichakravarthy N, Bal TR, Yogeeswari P. Synthesis of zidovudine prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Biomed Pharmacother 2005; 59: 452–455
- Sriram D, Yogeeswari P, Srichakravarthy N, Bal TR. Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Bioorg Med Chem Lett 2004; 14: 1085–1087
- Chu CK, Bhadti VS, Doshi KJ, Etse ET, Gallo JM, Boudinot FD, Schinazi RF. Brain targeting of anti-HIV nucleosides: Synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido-3′-deoxythymidine. J Med Chem 1990; 33: 2188–2192
- Barchi JJ, Marquez VE, Driscoll J, Ford H, Mitsuya H, Shirasaka T, Aoki S, Kelley JA. Potential anti-AIDS drugs: Lipophilic, adenosine deaminase-activated prodrugs. J Med Chem 1991; 34: 1647–1655
- Curley D, McGuigan C, Devine KG, OConnor TJ, Jeffriee DJ, Kinchington D. Synthesis and anti-HIV evaluation of some phosphoramidate derivatives of AZT studies on the effect of chain elongation on biological activity. Antiviral Res 1990; 14: 345–356
- Oldendorf WH. Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med 1974; 147: 813–815
- Sriram D, Bal TR, Yogeeswari P. Aminopyrimidinimino isatin analogues: Design of novel non- nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. Med Chem 2005; 20: 565–577
- Parang P, Wiebe LI, Knaus EE. Novel approaches for designing 5′-O-Ester prodrugs of 3′-Azido- 2′,3′-dideoxythymidine (AZT). Curr Med Chem 2000; 7: 995–1039
- Moss J, Bundgaard H. Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm Res 1990; 7: 885–892